What Happened?
Cambridge, -based Genocea Resigned Derek Meisner as Senior Vice President and General Counsel
About the Company
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
About the Person
Derek Meisner is Senior Vice President and General Counsel at X4 Pharmaceuticals. Previously, Derek held various senior legal leadership roles in the industry.
Info Source
News
Short Profile